Share Price and Basic Stock Data
Last Updated: November 4, 2025, 6:46 pm
| PEG Ratio | 2.04 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Blue Jet Healthcare Ltd operates in the pharmaceuticals sector, focusing on the production and distribution of healthcare products. The company’s reported sales for the fiscal year ending March 2025 stood at ₹1,030 Cr, marking a significant rise from ₹721 Cr in March 2023. This growth trajectory continues with trailing twelve months (TTM) sales at ₹1,222 Cr. Quarterly sales figures also reflect a positive trend, with the most recent quarter ending September 2024 recording sales of ₹208 Cr, up from ₹181 Cr in the previous quarter. This consistent sales growth indicates a robust demand for its products, positioning the company favorably within the competitive landscape of the pharmaceuticals industry. As Blue Jet continues to expand its market reach, its ability to maintain this upward trend will be critical for sustaining investor interest and enhancing its market share.
Profitability and Efficiency Metrics
Blue Jet Healthcare’s profitability metrics highlight its operational effectiveness. The company reported a net profit of ₹305 Cr for the fiscal year 2025, up from ₹160 Cr in March 2023, showcasing a strong recovery and growth in profitability. The operating profit margin (OPM) for the same period was 37%, demonstrating efficient management of costs relative to revenue. Moreover, the interest coverage ratio (ICR) stood at an impressive 40.49x, indicating that the company comfortably meets its interest obligations, reflecting strong operational cash flow. However, the cash conversion cycle (CCC) has lengthened to 262 days, which could pose challenges in working capital management. Despite this, the overall profitability and efficiency metrics position Blue Jet favorably against typical sector benchmarks, reinforcing its operational resilience.
Balance Sheet Strength and Financial Ratios
Blue Jet Healthcare’s balance sheet reflects a solid financial foundation, with total assets reported at ₹1,418 Cr for the fiscal year ending March 2025. The company maintains low borrowings of ₹21 Cr, resulting in a minimal debt-to-equity ratio, which enhances its financial stability. Reserves have increased significantly to ₹1,098 Cr, underpinning the company’s capacity for future investments and growth initiatives. Additionally, the return on equity (ROE) stood at an impressive 30.2%, indicating effective utilization of shareholder funds. However, the absence of a price-to-book value (P/BV) ratio may limit comparative analysis with peers. Overall, the company’s financial ratios and balance sheet strength reflect a robust position, making it an attractive proposition for potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Blue Jet Healthcare indicates a strong promoter presence, with promoters holding 79.81% of the equity as of September 2025. This high level of promoter ownership suggests a strong alignment of interests between management and shareholders, fostering investor confidence. Foreign institutional investors (FIIs) hold a modest 1.83%, while domestic institutional investors (DIIs) account for 3.63%. The public shareholding has increased to 14.74%, indicating growing interest from retail investors. The number of shareholders has also risen significantly to 80,117, reflecting increased market participation and confidence in the company’s prospects. This distribution of ownership can positively influence stock liquidity and overall market perception, reinforcing Blue Jet’s appeal as a stable investment.
Outlook, Risks, and Final Insight
Blue Jet Healthcare presents a promising outlook, bolstered by strong revenue growth and solid profitability metrics. However, the lengthening cash conversion cycle poses a potential risk, suggesting challenges in managing working capital effectively. Additionally, the company operates in a competitive pharmaceuticals market, where maintaining market share and profit margins can be challenging amid evolving regulatory landscapes. Despite these risks, the company’s robust financial health, as indicated by low debt levels and high ROE, provides a cushion against market volatility. Moving forward, strategic investments in product development and market expansion will be crucial for sustaining growth. If Blue Jet can enhance its operational efficiency and manage its cash flow effectively, it is well-positioned for continued success in the pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Blue Jet Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,021 Cr. | 461 | 479/192 | 113 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.0 Cr. | 45.9 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.8 Cr. | 24.4 | 29.1/17.0 | 37.3 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,834.08 Cr | 1,197.55 | 54.46 | 195.42 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 145 | 190 | 169 | 217 | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 |
| Expenses | 106 | 132 | 117 | 147 | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 |
| Operating Profit | 38 | 59 | 52 | 70 | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 |
| OPM % | 27% | 31% | 31% | 32% | 33% | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% |
| Other Income | 4 | 7 | 6 | 6 | 5 | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 6 | 6 | 7 | 6 | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 |
| Profit before tax | 36 | 59 | 51 | 70 | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 |
| Tax % | 24% | 26% | 27% | 27% | 24% | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% |
| Net Profit | 28 | 44 | 38 | 51 | 44 | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 |
| EPS in Rs | 1.61 | 2.53 | 2.16 | 2.92 | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 |
Last Updated: August 1, 2025, 6:00 am
Below is a detailed analysis of the quarterly data for Blue Jet Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 355.00 Cr.. The value appears strong and on an upward trend. It has increased from 340.00 Cr. (Mar 2025) to 355.00 Cr., marking an increase of 15.00 Cr..
- For Expenses, as of Jun 2025, the value is 234.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 200.00 Cr. (Mar 2025) to 234.00 Cr., marking an increase of 34.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 121.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2025) to 121.00 Cr., marking a decrease of 19.00 Cr..
- For OPM %, as of Jun 2025, the value is 34.00%. The value appears to be declining and may need further review. It has decreased from 41.00% (Mar 2025) to 34.00%, marking a decrease of 7.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 123.00 Cr.. The value appears to be declining and may need further review. It has decreased from 147.00 Cr. (Mar 2025) to 123.00 Cr., marking a decrease of 24.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 110.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 19.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.26. The value appears to be declining and may need further review. It has decreased from 6.35 (Mar 2025) to 5.26, marking a decrease of 1.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:44 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 1,222 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 767 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 454 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 37% |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 46 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 1 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 20 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 479 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 359 |
| EPS in Rs | 24,118.33 | 1,428.57 | 10.47 | 9.23 | 9.44 | 17.59 | 20.68 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2.07% | 28.17% | -12.09% | 2.50% | 85.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | 30.24% | -40.26% | 14.59% | 83.48% |
Blue Jet Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 76% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 19% |
| TTM: | 118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 27% |
| Last Year: | 31% |
Last Updated: September 5, 2025, 2:45 pm
Balance Sheet
Last Updated: September 10, 2025, 3:14 pm
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 |
| Borrowings | 74 | 53 | 19 | 5 | 3 | 21 |
| Other Liabilities | 92 | 143 | 173 | 176 | 211 | 263 |
| Total Liabilities | 364 | 536 | 713 | 862 | 1,059 | 1,418 |
| Fixed Assets | 107 | 0 | 156 | 151 | 172 | 300 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 |
| Other Assets | 229 | 497 | 460 | 491 | 489 | 841 |
| Total Assets | 364 | 536 | 713 | 862 | 1,059 | 1,418 |
Below is a detailed analysis of the balance sheet data for Blue Jet Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 35.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,098.00 Cr.. The value appears strong and on an upward trend. It has increased from 811.00 Cr. (Mar 2024) to 1,098.00 Cr., marking an increase of 287.00 Cr..
- For Borrowings, as of Mar 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 18.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 263.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 211.00 Cr. (Mar 2024) to 263.00 Cr., marking an increase of 52.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,418.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,059.00 Cr. (Mar 2024) to 1,418.00 Cr., marking an increase of 359.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 300.00 Cr.. The value appears strong and on an upward trend. It has increased from 172.00 Cr. (Mar 2024) to 300.00 Cr., marking an increase of 128.00 Cr..
- For CWIP, as of Mar 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 147.00 Cr. (Mar 2024) to 89.00 Cr., marking a decrease of 58.00 Cr..
- For Investments, as of Mar 2025, the value is 187.00 Cr.. The value appears to be declining and may need further review. It has decreased from 250.00 Cr. (Mar 2024) to 187.00 Cr., marking a decrease of 63.00 Cr..
- For Other Assets, as of Mar 2025, the value is 841.00 Cr.. The value appears strong and on an upward trend. It has increased from 489.00 Cr. (Mar 2024) to 841.00 Cr., marking an increase of 352.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,418.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,059.00 Cr. (Mar 2024) to 1,418.00 Cr., marking an increase of 359.00 Cr..
Notably, the Reserves (1,098.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | 140.00 | 154.00 | 230.00 | 214.00 | 228.00 | 357.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 |
| Inventory Days | 120 | 201 | 133 | 137 | 151 | 209 |
| Days Payable | 90 | 101 | 72 | 58 | 35 | 70 |
| Cash Conversion Cycle | 110 | 204 | 183 | 199 | 206 | 262 |
| Working Capital Days | 55 | 105 | 103 | 120 | 92 | 157 |
| ROCE % | 58% | 53% | 35% | 30% | 40% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,080,413 | 1.01 | 37.17 | 1,080,413 | 2025-04-22 15:56:51 | 0% |
| ICICI Prudential Innovation Fund | 732,067 | 0.6 | 25.18 | 732,067 | 2025-04-22 17:25:13 | 0% |
| HDFC Business Cycle Fund | 367,344 | 0.43 | 12.64 | 367,344 | 2025-04-22 17:25:13 | 0% |
| Bandhan Small Cap Fund | 285,391 | 0.22 | 9.82 | 285,391 | 2025-04-22 17:25:13 | 0% |
| Edelweiss Recently Listed IPO Fund | 231,403 | 0.84 | 7.96 | 231,403 | 2025-04-22 15:56:51 | 0% |
| Edelweiss Aggressive Hybrid Fund | 144,480 | 0.37 | 4.97 | 144,480 | 2025-04-22 17:25:13 | 0% |
| Edelweiss Aggressive Hybrid Fund - Plan B | 144,480 | 0.37 | 4.97 | 144,480 | 2025-04-22 15:56:51 | 0% |
Key Financial Ratios
| Month | Mar 21 | Mar 20 |
|---|---|---|
| FaceValue | 100.00 | 100.00 |
| Basic EPS (Rs.) | 1396.27 | 1462.59 |
| Diluted EPS (Rs.) | 1396.27 | 1462.59 |
| Cash EPS (Rs.) | 1568.30 | 27166.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3428.34 | 32238.33 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3428.34 | 32238.33 |
| Revenue From Operations / Share (Rs.) | 5033.61 | 89699.16 |
| PBDIT / Share (Rs.) | 2168.43 | 36589.16 |
| PBIT / Share (Rs.) | 1970.05 | 33582.66 |
| PBT / Share (Rs.) | 1862.96 | 32354.50 |
| Net Profit / Share (Rs.) | 1369.92 | 24159.83 |
| NP After MI And SOA / Share (Rs.) | 1396.43 | 24141.33 |
| PBDIT Margin (%) | 43.07 | 40.79 |
| PBIT Margin (%) | 39.13 | 37.43 |
| PBT Margin (%) | 37.01 | 36.07 |
| Net Profit Margin (%) | 27.21 | 26.93 |
| NP After MI And SOA Margin (%) | 27.74 | 26.91 |
| Return on Networth / Equity (%) | 40.73 | 75.40 |
| Return on Capital Employeed (%) | 52.32 | 83.21 |
| Return On Assets (%) | 25.94 | 38.58 |
| Long Term Debt / Equity (X) | 0.08 | 0.19 |
| Total Debt / Equity (X) | 0.10 | 0.30 |
| Asset Turnover Ratio (%) | 1.10 | 0.00 |
| Current Ratio (X) | 2.43 | 1.89 |
| Quick Ratio (X) | 1.69 | 1.37 |
| Inventory Turnover Ratio (X) | 2.30 | 0.00 |
| Interest Coverage Ratio (X) | 40.49 | 29.79 |
| Interest Coverage Ratio (Post Tax) (X) | 27.58 | 20.67 |
After reviewing the key financial ratios for Blue Jet Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 21, the value is 100.00. This value exceeds the healthy maximum of 10. There is no change compared to the previous period (Mar 20) which recorded 100.00.
- For Basic EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
- For Diluted EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
- For Cash EPS (Rs.), as of Mar 21, the value is 1,568.30. This value is within the healthy range. It has decreased from 27,166.33 (Mar 20) to 1,568.30, marking a decrease of 25,598.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
- For Revenue From Operations / Share (Rs.), as of Mar 21, the value is 5,033.61. It has decreased from 89,699.16 (Mar 20) to 5,033.61, marking a decrease of 84,665.55.
- For PBDIT / Share (Rs.), as of Mar 21, the value is 2,168.43. This value is within the healthy range. It has decreased from 36,589.16 (Mar 20) to 2,168.43, marking a decrease of 34,420.73.
- For PBIT / Share (Rs.), as of Mar 21, the value is 1,970.05. This value is within the healthy range. It has decreased from 33,582.66 (Mar 20) to 1,970.05, marking a decrease of 31,612.61.
- For PBT / Share (Rs.), as of Mar 21, the value is 1,862.96. This value is within the healthy range. It has decreased from 32,354.50 (Mar 20) to 1,862.96, marking a decrease of 30,491.54.
- For Net Profit / Share (Rs.), as of Mar 21, the value is 1,369.92. This value is within the healthy range. It has decreased from 24,159.83 (Mar 20) to 1,369.92, marking a decrease of 22,789.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 21, the value is 1,396.43. This value is within the healthy range. It has decreased from 24,141.33 (Mar 20) to 1,396.43, marking a decrease of 22,744.90.
- For PBDIT Margin (%), as of Mar 21, the value is 43.07. This value is within the healthy range. It has increased from 40.79 (Mar 20) to 43.07, marking an increase of 2.28.
- For PBIT Margin (%), as of Mar 21, the value is 39.13. This value exceeds the healthy maximum of 20. It has increased from 37.43 (Mar 20) to 39.13, marking an increase of 1.70.
- For PBT Margin (%), as of Mar 21, the value is 37.01. This value is within the healthy range. It has increased from 36.07 (Mar 20) to 37.01, marking an increase of 0.94.
- For Net Profit Margin (%), as of Mar 21, the value is 27.21. This value exceeds the healthy maximum of 10. It has increased from 26.93 (Mar 20) to 27.21, marking an increase of 0.28.
- For NP After MI And SOA Margin (%), as of Mar 21, the value is 27.74. This value exceeds the healthy maximum of 20. It has increased from 26.91 (Mar 20) to 27.74, marking an increase of 0.83.
- For Return on Networth / Equity (%), as of Mar 21, the value is 40.73. This value is within the healthy range. It has decreased from 75.40 (Mar 20) to 40.73, marking a decrease of 34.67.
- For Return on Capital Employeed (%), as of Mar 21, the value is 52.32. This value is within the healthy range. It has decreased from 83.21 (Mar 20) to 52.32, marking a decrease of 30.89.
- For Return On Assets (%), as of Mar 21, the value is 25.94. This value is within the healthy range. It has decreased from 38.58 (Mar 20) to 25.94, marking a decrease of 12.64.
- For Long Term Debt / Equity (X), as of Mar 21, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 20) to 0.08, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 21, the value is 0.10. This value is within the healthy range. It has decreased from 0.30 (Mar 20) to 0.10, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 21, the value is 1.10. It has increased from 0.00 (Mar 20) to 1.10, marking an increase of 1.10.
- For Current Ratio (X), as of Mar 21, the value is 2.43. This value is within the healthy range. It has increased from 1.89 (Mar 20) to 2.43, marking an increase of 0.54.
- For Quick Ratio (X), as of Mar 21, the value is 1.69. This value is within the healthy range. It has increased from 1.37 (Mar 20) to 1.69, marking an increase of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 21, the value is 2.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 20) to 2.30, marking an increase of 2.30.
- For Interest Coverage Ratio (X), as of Mar 21, the value is 40.49. This value is within the healthy range. It has increased from 29.79 (Mar 20) to 40.49, marking an increase of 10.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 21, the value is 27.58. This value is within the healthy range. It has increased from 20.67 (Mar 20) to 27.58, marking an increase of 6.91.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Blue Jet Healthcare Ltd:
- Net Profit Margin: 27.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.32% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 40.73% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 27.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.8 (Industry average Stock P/E: 54.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.1
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 27.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 701, 702, 7th Floor, Navi Mumbai Maharashtra 400705 | companysecretary@bluejethealthcare.com http://www.bluejethealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Akshay Bansarilal Arora | Executive Chairman |
| Mr. Shiven Akshay Arora | Managing Director |
| Mr. Naresh Suryakant Shah | Executive Director |
| Mr. Popat B Kedar | Executive Director |
| Ms. Divya Sameer Momaya | Independent Director |
| Mr. Girish Paman Vanvari | Independent Director |
| Ms. Preeti Gautam Mehta | Independent Director |
| Ms. Priyanka Yadav | Independent Director |
FAQ
What is the intrinsic value of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd's intrinsic value (as of 04 November 2025) is 522.30 which is 13.95% lower the current market price of 607.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 10,512 Cr. market cap, FY2025-2026 high/low of 1,028/470, reserves of ₹1,098 Cr, and liabilities of 1,418 Cr.
What is the Market Cap of Blue Jet Healthcare Ltd?
The Market Cap of Blue Jet Healthcare Ltd is 10,512 Cr..
What is the current Stock Price of Blue Jet Healthcare Ltd as on 04 November 2025?
The current stock price of Blue Jet Healthcare Ltd as on 04 November 2025 is 607.
What is the High / Low of Blue Jet Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Blue Jet Healthcare Ltd stocks is 1,028/470.
What is the Stock P/E of Blue Jet Healthcare Ltd?
The Stock P/E of Blue Jet Healthcare Ltd is 29.8.
What is the Book Value of Blue Jet Healthcare Ltd?
The Book Value of Blue Jet Healthcare Ltd is 72.4.
What is the Dividend Yield of Blue Jet Healthcare Ltd?
The Dividend Yield of Blue Jet Healthcare Ltd is 0.20 %.
What is the ROCE of Blue Jet Healthcare Ltd?
The ROCE of Blue Jet Healthcare Ltd is 39.8 %.
What is the ROE of Blue Jet Healthcare Ltd?
The ROE of Blue Jet Healthcare Ltd is 30.2 %.
What is the Face Value of Blue Jet Healthcare Ltd?
The Face Value of Blue Jet Healthcare Ltd is 2.00.